Literature DB >> 31420651

Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases.

David P Serota1, Joshua A Barocas2,3, Sandra A Springer4.   

Abstract

Infectious diseases (ID) physicians are increasingly responsible for the management of infectious consequences of substance use disorders (SUD). While we are often consulted for diagnosis and treatment of the infectious disease, it is clear that successful management of these infections requires a holistic approach, including acknowledgement and treatment of the underlying SUD. As we have learned through years of treating human immunodeficiency virus and hepatitis C virus infections, ID physicians have unique expertise in addressing both the infection and the complex biopsychosocial factors that underpin the infection. Many ID physicians have incorporated the management of addiction as part of their scope of practice, and here we seek to give a name and define the role of these ID/addiction dual specialists. We define the potential role of ID/addiction physicians in clinical care, health administration, and research, as well as provide recommendations to bolster the supply and reach of this burgeoning subspecialty.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  addiction; endocarditis; injection drug use; opioids; substance use disorders

Year:  2020        PMID: 31420651      PMCID: PMC7319263          DOI: 10.1093/cid/ciz804

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.

Authors:  Sandra A Springer; Angela Di Paola; Russell Barbour; Marwan M Azar; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

2.  Many Opportunities to Record, Diagnose, or Treat Injection Drug-related Infections Are Missed: A Population-based Cohort Study of Inpatient and Emergency Department Settings.

Authors:  Aaron C Miller; Philip M Polgreen
Journal:  Clin Infect Dis       Date:  2019-03-19       Impact factor: 9.079

3.  Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver.

Authors:  Kevin Fiscella; Sarah E Wakeman; Leo Beletsky
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596

Review 4.  In the Clinic. Substance Use Disorders.

Authors:  Christine A Pace; Jeffrey H Samet
Journal:  Ann Intern Med       Date:  2016-04-05       Impact factor: 25.391

5.  Endocarditis in the setting of IDU: multidisciplinary management.

Authors:  Bobby Yanagawa; Anees Bahji; Wiplove Lamba; Darrell H Tan; Asim Cheema; Ishba Syed; Subodh Verma
Journal:  Curr Opin Cardiol       Date:  2018-03       Impact factor: 2.161

6.  Impact of a brief addiction medicine training experience on knowledge self-assessment among medical learners.

Authors:  Jan Klimas; Keith Ahamad; Christoper Fairgrieve; Mark McLean; Annabel Mead; Seonaid Nolan; Evan Wood
Journal:  Subst Abus       Date:  2017-02-21       Impact factor: 3.716

7.  Ryan White HIV/AIDS Program Assistance and HIV Treatment Outcomes.

Authors:  Heather Bradley; Abigail H Viall; Pascale M Wortley; Antigone Dempsey; Heather Hauck; Jacek Skarbinski
Journal:  Clin Infect Dis       Date:  2015-08-30       Impact factor: 9.079

8.  Substance Use Disorder Assessment, Diagnosis, and Management for Patients Hospitalized With Severe Infections Due to Injection Drug Use.

Authors:  Crystal Jicha; David Saxon; Michelle R Lofwall; Laura C Fanucchi
Journal:  J Addict Med       Date:  2019 Jan/Feb       Impact factor: 3.702

9.  Bacterial and Fungal Infections in Persons Who Inject Drugs - Western New York, 2017.

Authors:  Kathleen P Hartnett; Kelly A Jackson; Christina Felsen; Robert McDonald; Ana Cecilia Bardossy; Runa H Gokhale; Ian Kracalik; Todd Lucas; Olivia McGovern; Chris A Van Beneden; Michael Mendoza; Michele Bohm; John T Brooks; Alice K Asher; Shelley S Magill; Anthony Fiore; Debra Blog; Elizabeth M Dufort; Isaac See; Ghinwa Dumyati
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-07-05       Impact factor: 17.586

10.  Clinical Characteristics and Factors Associated With Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs.

Authors:  Laura Rodger; Stephannie Dresden Glockler-Lauf; Esfandiar Shojaei; Adeel Sherazi; Brian Hallam; Sharon Koivu; Kaveri Gupta; Seyed M Hosseini-Moghaddam; Michael Silverman
Journal:  JAMA Netw Open       Date:  2018-11-02
View more
  19 in total

1.  Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!

Authors:  Sandra A Springer; Carlos Del Rio
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

Review 2.  A Taxonomy of Hospital-Based Addiction Care Models: a Scoping Review and Key Informant Interviews.

Authors:  Honora Englander; Amy Jones; Noa Krawczyk; Alisa Patten; Timothy Roberts; P Todd Korthuis; Jennifer McNeely
Journal:  J Gen Intern Med       Date:  2022-05-09       Impact factor: 6.473

3.  Bacterial Infections Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012-2017.

Authors:  Natalie L McCarthy; James Baggs; Isaac See; Sujan C Reddy; John A Jernigan; Runa H Gokhale; Anthony E Fiore
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

Review 4.  Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments.

Authors:  Asher Schranz; Joshua A Barocas
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

5.  Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder.

Authors:  Nikhil Seval; Cynthia A Frank; Alain H Litwin; Prerana Roth; Meredith A Schade; Martina Pavlicova; Frances R Levin; Kathleen T Brady; Edward V Nunes; Sandra A Springer
Journal:  Contemp Clin Trials       Date:  2021-04-07       Impact factor: 2.261

6.  Surgeons' Perspectives on Valve Surgery in People With Drug Use-Associated Infective Endocarditis.

Authors:  Alysse G Wurcel; Julia Zubiago; Jessica Reyes; Emma Smyth; Keki R Balsara; Danielle Avila; Joshua A Barocas; Curt G Beckwith; Jenny Bui; Cody A Chastain; Ellen F Eaton; Simeon Kimmel; Molly L Paras; Asher J Schranz; Darshali A Vyas; Alison Rapoport
Journal:  Ann Thorac Surg       Date:  2022-01-31       Impact factor: 5.102

Review 7.  Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases.

Authors:  Nikhil Seval; Ellen Eaton; Sandra A Springer
Journal:  Open Forum Infect Dis       Date:  2019-12-24       Impact factor: 3.835

8.  Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.

Authors:  Haesuk Park; Hyun Jin Song; Xinyi Jiang; Linda Henry; Robert L Cook; David R Nelson
Journal:  Hepatol Commun       Date:  2020-11-17

9.  Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018.

Authors:  Jeffrey Capizzi; Judith Leahy; Haven Wheelock; Jonathan Garcia; Luke Strnad; Monica Sikka; Honora Englander; Ann Thomas; P Todd Korthuis; Timothy William Menza
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

10.  Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders.

Authors:  Xinyi Jiang; Robert L Parker; Scott Martin Vouri; Weihsuan Lo-Ciganic; Vakaramoko Diaby; Linda Henry; Haesuk Park
Journal:  Am J Prev Med       Date:  2021-06-29       Impact factor: 6.604

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.